The phase III TRIPLETE study shows that upfront mFOLFOXIRI plus panitumumab improved overall survival in patients with metastatic colorectal cancer compared to mFOLFOX plus panitumumab. The experimental regimen resulted in a longer median overall survival of 41.1 months compared to 33.3 months and a higher postprogression survival of 24.6 months. However, the safety profile demonstrated higher rates of grade 3 or higher adverse events such as diarrhea and neutropenia in the experimental group.
Study
|
Phase III randomized study [TRIPLETE; NCT03231722] |
| Patients with RAS/BRAF wild-type metastatic colorectal cancer |
| mFOLFOXIRI+panitumumab (n=218) vs mFOLFOX+panitumumab (n=217)
|
Efficacy
|
ORR: 75% vs 78% (OR 0.84 [0.54-1.31]) |
| mOS: 41.1 mos vs 33.3 mos (HR 0.79 [0.63-0.99]) |
| mPFS: 12.7 mos vs 12.4 mos (HR 0.95 [0.78-1.16]) |
| Median postprogression survival: 24.6 mos vs 17.7 mos (HR 0.79 [0.62-1.01])
|
Safety
|
Grade >=3 AEs: Diarrhea (25% vs 8%), Neutropenia (33% vs 20%) |
| Nausea (5% vs 2%), Vomiting (2% vs 1%), Stomatitis (7% vs 7%)
|
J Clin Oncol. Published online January 8, 2026.
http://doi.org/10.1200/JCO-25-01337
Reviewed by Ulas D. Bayraktar, MD on Jan 21, 2026
